Progress in the treatment of relapsed or refractory Hodgkin's lymphoma

This article is from the NEJM Journal Watch Progress in Treatment for Relapsed or Refractory Hodgkin Lymphoma.
Commentary author: Michael E.
Williams, MD, ScM patients receiving Verbutor After the second-line treatment with cilimab + nivolumab and subsequent autologous stem cell transplantation, the 3-year overall survival rate was 93%
.

Although most patients with Hodgkin's lymphoma can be cured by first-line treatment, patients with primary drug resistance or later relapse have a poor prognosis
.

Now, researchers report the recurrence or recurrence of receiving anti-CD30 antibody drug conjugate vebutuximab (BV) + anti-PD-1 monoclonal antibody nivolumab (Nivo) (sequential or combination) treatment Long-term follow-up results of patients with refractory Hodgkin’s lymphoma
.

This phase 1 to 2 multicenter trial funded by the industry in the United States excluded patients who had previously received second-line radiotherapy, chemotherapy/immunotherapy, or allogeneic or autologous stem cell transplantation (ASCT); one cohort excluded those who had previously received BV treatment Patients, and another cohort included patients who had previously received BV treatment, provided that the patient did not tolerate BV and did not suffer from BV refractory disease
.

In this trial, patients were given up to four cycles of BV/Nivo treatment, and patients who achieved remission received subsequent ASCT consolidation therapy
.

The median age of the 93 patients included in this trial was 34 years, and the median follow-up time was 34.
3 months
.

Ninety-one patients completed the planned BV/Nivo treatment, and 67 patients (74%) received ASCT directly afterwards; another 17 patients (19%) received other salvage treatments before receiving ASCT treatment
.

The total remission rate of patients receiving BV/Nivo treatment was 85%, and the complete remission rate was 67%; the incidence of disease progression or death was 18%
.

The 3-year progression-free survival rate of all patients was 77%, and the 3-year progression-free survival rate of patients who received ASCT directly after BV/Nivo treatment was 91%; the 3-year overall survival rate was 93%
.

No unexpected short-term or long-term toxicity was observed in this test
.

Commenting on these results and the results of other recent studies indicate that BV/Nivo is a very effective non-cytotoxic second-line treatment for relapsed or refractory Hodgkin’s lymphoma
.

As the comment writer pointed out, many patients now receive first-line combination therapy that includes BV
.

We need more data to determine the response and outcome of these patients to BV/Nivo treatment
.

Commented article Advani RH et al.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood 2021 Aug 12; 138:427.
(https://doi.
org/10.
1182/blood.
2020009178 )Choi Y and Diefenbach C.
Expanding landscape for relapsed Hodgkin lymphoma.
Blood 2021 Aug 12; 138:421.
(https://doi.
org/10.
1182/blood.
2021011774) Published by NEJM Group, internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.

"NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.

Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.

The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.

If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.

Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.